To see the other types of publications on this topic, follow the link: Meldonium (mildronate).

Journal articles on the topic 'Meldonium (mildronate)'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 21 journal articles for your research on the topic 'Meldonium (mildronate).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Vertkin, A. L., N. O. Khovasova, V. V. Pshenichnikova, M. A. Alekseev, and A. U. Abdullaeva. "MELDONIUM: EFFECTIVE ACTION POINTS." Cardiovascular Therapy and Prevention 12, no. 2 (2013): 94–97. http://dx.doi.org/10.15829/1728-8800-2013-2-94-97.

Full text
Abstract:
The paper is focused on hypoxia and cell ischemia as universal pathogenetic mechanisms of disease development, which can be addressed by both etiotropic and pathogenetic therapy. The latter is represented by the so-called metabolic correctors. At present, one of the most widely used metabolic correctors is mildronate. The authors discuss the effectiveness of mildronate in various clinical situations and also present the relevant original findings.
APA, Harvard, Vancouver, ISO, and other styles
2

Jargin, Sergei V. "Meldonium (Mildronate): Primum nоn nocere". Pharmacological Research 114 (грудень 2016): 294. http://dx.doi.org/10.1016/j.phrs.2016.10.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Greenblatt, H. Karl, and David J. Greenblatt. "Meldonium (Mildronate): A Performance-Enhancing Drug?" Clinical Pharmacology in Drug Development 5, no. 3 (2016): 167–69. http://dx.doi.org/10.1002/cpdd.264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tolstov, S. N., and V. B. Mychka. "Metabolic (cytoprotective) therapy of menopausal disturbances." Cardiovascular Therapy and Prevention 10, no. 3 (2011): 72–75. http://dx.doi.org/10.15829/1728-8800-2011-3-72-75.

Full text
Abstract:
The paper presents modern views on cardiovascular aspects of menopause and metabolic therapy of menopausal disturbances with meldonium (Mildronate®). The role of estrogen deficiency in climacteric disturbance development, key pathogenetic mechanisms of menopausal metabolic syndrome (MS), and relevant features of arterial hypertension and endothelial dysfunction development are discussed. The data on Mildronate® clinical use for cardiovascular prevention are summarized. The wide prevalence and multiple clinical manifestations of menopausal disturbances point to the need for their complex therap
APA, Harvard, Vancouver, ISO, and other styles
5

Ahmad, Asrar, Clemilson Berto-Junior, Papa Hoyeck, Namita Kumari, Marina Jerebtsova, and Sergei Nekhai. "Mildronate Ameliorates Kidney Function and Reduces Inflammation in SCD Mice." Blood 142, Supplement 1 (2023): 5274. http://dx.doi.org/10.1182/blood-2023-186459.

Full text
Abstract:
INTRODUCTION:Sickle cell disease (SCD) is a genetic hemoglobin disorder characterized by hemolytic anemia, vaso-occlusive crisis and inflammation that affects organs such as the kidney, liver, brain, spleen, and heart. SCD is driven by a mutation in the β-globin gene that causes sickling of red blood cells (RBCs). More than 50% of SCD patients are affected by chronic kidney diseases (CKD) and other comorbidities. Vasculopathy is caused by hemolysis-related endothelial dysfunction and inflammation, which collectively contribute to the development of renal disease. Mildronate (also known as Meld
APA, Harvard, Vancouver, ISO, and other styles
6

Berlato, Dener Gomes, and André Valle de Bairros. "Meldonium: Pharmacological, toxicological, and analytical aspects." Toxicology Research and Application 4 (January 1, 2020): 239784732091514. http://dx.doi.org/10.1177/2397847320915143.

Full text
Abstract:
Meldonium is the active molecule from Mildronate® with similar chemical structure to an amino acid, and it is known as (3-(2,2,2-trimethylhydrazine) propionate) (CAS 76144-81-5). This pharmaceutical substance is approved in Eastern Europe for cerebral and myocardial ischemia and has been on the World Doping Association’s banned substances list since January 2016. The goal of this review is to relate the use of meldonium as a doping agent, considering its pharmacological, toxicological, and analytical aspects. This review is based on the scientific literature from digital platforms. The main me
APA, Harvard, Vancouver, ISO, and other styles
7

Axmedov, Shamshod Jamshidovich. "EFFECTS OF THE DRUG MILDRONATE." Innovative Development in Educational Activities 2, no. 20 (2023): 40–59. https://doi.org/10.5281/zenodo.10047158.

Full text
Abstract:
<i>Mildronate (3-(2,2,2-trimethylhydrazine) propionate; THP; MET-88; meldonium, quaterine) is an anti-ischemic drug developed in the Latvian Institute of Organic Synthesis. Mildronate was designed as a promising inhibitor of carnitine biosynthesis aimed to prevent accumulation of cytotoxic intermediate products of fatty acid beta- oxidation in ischemic tissues and to block this highly oxygenconsuming process. Actually Mildronate is used in several countries in cardiology (treatment of chronic heart ischemic disease, stable angina pectoris, chronic heart failure, functional disorders of heart a
APA, Harvard, Vancouver, ISO, and other styles
8

Kuprash, Liana, Olena Kuprash, and Svetlana Gudarenko. "Metabolic cardiocytoprotectors (trimetazidine and trimethylhydrazine) in geriatrics. Short review." Issue 2 2022, no. 2 2022 (June 7, 2022): 63–70. http://dx.doi.org/10.47855/jal9020-2022-2-5.

Full text
Abstract:
The review presents the clinical studies results of the effectiveness of cardiocytoprotectors, fatty acids synthesis inhibitors, trimetazidine (preductal), and trimethylhydrazine (meldonium, mildronate) in the treatment of cardiovascular disease (angina pectoris, chronic heart failure) and the central nervous system disease (dyscirculatory encephalopathy, chronic cerebral insufficiency, stroke) various ages patients. These data indicate the prospects of using these drugs in the complex therapy of cardiovascular and cerebrovascular diseases in the geriatric clinic. Keywords: metabolic cardiocyt
APA, Harvard, Vancouver, ISO, and other styles
9

Horyn, Mariana, Marjan Piponski, Olha Poliak, Nataliia Shulyak, Marta Sulyma, and Liliya Logoyda. "Development of the spectrophotometric method for the determination of meldonium in capsules by using alizarine." ScienceRise: Pharmaceutical Science, no. 1(47) (February 29, 2024): 12–19. http://dx.doi.org/10.15587/2519-4852.2024.299165.

Full text
Abstract:
The aim of the work was to develop a simple, rapid, economic spectrophotometric method for the determination of meldonium in capsules based on the reaction with alizarin.&#x0D; Materials and methods. Analytical equipment: double-beam UV-visible spectrophotometer Shimadzu UV 1800 (Japan), a pair of 1 cm matched quartz cells, software UV-Probe 2.62, laboratory electronic balance RAD WAG AS 200/C, pH-meter И-160МИ. Pharmacopoeial standard sample (CRS) of meldonium dihydrate (Sigma-Aldrich, (≥ 98 %, HPLC)), alizarin (Synbias), capsules Metamax (Darnytsia) 250 mg, Vasopro (Farmak) 500 mg, Mildronat
APA, Harvard, Vancouver, ISO, and other styles
10

Litvinova, S. V., O. D. Ostroumova, A. I. Kochetkov, E. V. Mironova, and I. I. Sinitsyna. "Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity." Russian Journal of Cardiology and Cardiovascular Surgery 18, no. 1 (2025): 53. https://doi.org/10.17116/kardio20251801153.

Full text
Abstract:
Relevance. Cardiovascular diseases, including coronary heart disease (CHD), remain the leading causes of death worldwide. At the same time, concomitant obesity further increases the risk of adverse cardiovascular events (CVE) and complicates the management of these patients. One of the strategies aimed at increasing the effectiveness of CHD treatment is the use of metabolic therapy to ensure cardiocytoprotection. Aim. To study the effect of the drug Mildronate on the quality of life of patients with coronary heart disease and chronic heart failure (CHF) suffering from obesity. Material and met
APA, Harvard, Vancouver, ISO, and other styles
11

Dambrova, Maija, та Edgars Liepinsh. "Response to comment by Sergei V. Jargin: “Meldonium (Mildronate): primum nоn nocere”". Pharmacological Research 114 (грудень 2016): 295–96. http://dx.doi.org/10.1016/j.phrs.2016.10.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Grigoryan, S. V., L. G. Hazarapetyan, and A. A. Stepanyan. "An Experience of Meldonium Use in Patients with Ventricular Arrhythmias of Ischemic Genesis." Kardiologiia 59, no. 7 (2019): 26–30. http://dx.doi.org/10.18087/cardio.2019.7.n552.

Full text
Abstract:
Ischemic heart disease (IHD) is often accompanied by cardiac rhythm disturbances particularly ventricular arrhythmias (VA) and their appearance in both chronic and acute forms of IHD is usually regarded as dangerous signal requiring the use of antiarrhythmic drugs. An important addition to hemodynamic therapy can be considered the use of cytoprotective drugs that improve the energy potential of cardiomyocytes. The purpose of this work is to study the comparative evaluation of the Mildronate effectiveness in patients with IHD and VA.Methods.Under dynamic observation were 147 patients with IHD a
APA, Harvard, Vancouver, ISO, and other styles
13

Chetrus, Olga, Ghenadii Calin, Oxana Sirbu, Diana Sasu, Svetlana Gavriliuc, and Valeriu Istrati. "Influence of the cytoprotective drug meldonium on diastolic dysfunction of the myocardium." Moldovan Medical Journal 66, no. 2 (2023): 24–28. http://dx.doi.org/10.52418/moldovan-med-j.66-2.23.04.

Full text
Abstract:
Background: The use of myocardial cytoprotectors (meldonium) in patients with exertional angina is a scientific-practical dilemma. Material and methods: An open randomized clinical trial was conducted involving 160 patients with chronic heart faliure (117 men and 43 women) aged 37 to 81 years. Of them, 142 patients had angina pectoris of stable effort from different functional classes, and 21 – unstable angina pectoris. Study groups were comparable according to the frequency of indication of background drugs and meldonium. Results: The number of patients with normal diastolic function in both
APA, Harvard, Vancouver, ISO, and other styles
14

Bryushinina, O. S., E. A. Yanovskaya, Yu G. Zyuz’kova, N. Yu Abdrashitova, G. A. Frelikh, and V. V. Udut. "Comparative Study of the Pharmacokinetics and Bioequivalence of Meldonium and Mildronate® Preparations." Pharmaceutical Chemistry Journal 54, no. 9 (2020): 877–82. http://dx.doi.org/10.1007/s11094-020-02291-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Tastekova, Elina A., Alexander Yu Polyakov, Anastasia E. Goldt, et al. "Facile chemical routes to mesoporous silver substrates for SERS analysis." Beilstein Journal of Nanotechnology 9 (March 14, 2018): 880–89. http://dx.doi.org/10.3762/bjnano.9.82.

Full text
Abstract:
Mesoporous silver nanoparticles were easily synthesized through the bulk reduction of crystalline silver(I) oxide and used for the preparation of highly porous surface-enhanced Raman scattering (SERS)-active substrates. An analogous procedure was successfully performed for the production of mesoporous silver films by chemical reduction of oxidized silver films. The sponge-like silver blocks with high surface area and the in-situ-prepared mesoporous silver films are efficient as both analyte adsorbents and Raman signal enhancement mediators. The efficiency of silver reduction was characterized
APA, Harvard, Vancouver, ISO, and other styles
16

Tretzel, L., C. Görgens, H. Geyer, et al. "Analyses of Meldonium (Mildronate) from Blood, Dried Blood Spots (DBS), and Urine Suggest Drug Incorporation into Erythrocytes." International Journal of Sports Medicine 37, no. 06 (2016): 500–502. http://dx.doi.org/10.1055/s-0036-1582317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Görgens, Christian, Sven Guddat, Josef Dib, Hans Geyer, Wilhelm Schänzer, and Mario Thevis. "Mildronate (Meldonium) in professional sports – monitoring doping control urine samples using hydrophilic interaction liquid chromatography – high resolution/high accuracy mass spectrometry." Drug Testing and Analysis 7, no. 11-12 (2015): 973–79. http://dx.doi.org/10.1002/dta.1788.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Maksvytytė, Šarūnė, and Pranas Šerpytis. "MELDONIUMAS KARDIOVASKULINIŲ IR NEUROLOGINIŲ LIGŲ BEI CUKRINIO DIABETO GYDYMUI." Health Sciences 31, no. 4 (2021): 52–55. http://dx.doi.org/10.35988/sm-hs.2021.120.

Full text
Abstract:
Meldoniumas (farmacinis vaisto pavadinimas – mildronatas) – tai veiklioji medžiaga, mažinanti L-karnitino koncentraciją kraujo plazmoje ir audiniuose, pasižyminti metabolizmą moduliuojančiu efektu. Dėl fizinį pajėgumą didinančio poveikio šis vaistas pasaulinės dopingo agentūros įrašytas į draudžiamųjų medžiagų sąrašą. Šiuo metu vienintelė Lietuvoje registruojama terapinė meldoniumo indikacija – papildomas lengvo lėtinio širdies nepakankamumo gydymas. Meldoniumo farmakologinės savybės ir galimas potencialas gydant įvairias ligas kol kas ištyrinėtas nepakankamai, todėl pastaruoju metu dėl savo v
APA, Harvard, Vancouver, ISO, and other styles
19

Heylo, Heylo T. S., Danilogorskaya Yu A. Danilogorskaya, Nazarenko G. B. Nazarenko, and Martynov A. I. Martynov. "Estimation of the influence of 6 week therapy by meldonium (Mildronate®) at bulbar capillaroscopy indexes in chronic ischemic heart and brain disease female patient." Therapy 3_2020 (May 14, 2020): 105–10. http://dx.doi.org/10.18565/therapy.2020.3.105-110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Tanashyan, M. M., M. Yu Maksimova, A. A. Shabalina, P. A. Fedin, R. B. Medvedev, and T. A. Bolotova. "Chronic cerebrovascular diseases and neuroprotection: the clinical efficacy of meldonium (Mildronat)." Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120, no. 10 (2020): 14. http://dx.doi.org/10.17116/jnevro202012010114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Nekhai, Sergei, Asrar Ahmad, Clemilson Berto-Junior, Papa Hoyeck, Namita Kumari, and Marina Jerebtsova. "Mildronate ameliorates kidney injury and reduces inflammation in Sickle Cell Disease mice." Physiology 39, S1 (2024). http://dx.doi.org/10.1152/physiol.2024.39.s1.1512.

Full text
Abstract:
INTRODUCTION: Sickle cell disease (SCD) is a hereditary hemoglobin disorder characterized by hemolytic anemia, vaso-occlusive crisis and chronic inflammation that affects multiple organs including kidney, liver, brain, spleen, and heart. Renal disease, the most common complication in SCD, is a progressive disease that begins in childhood as glomerular hyperfiltration, then advances to albuminuria, following by a fast decline in glomerular filtration. It may further progress to a renal failure in adults. More than 50% of SCD patients develop chronic kidney disease (CKD), and 14-18% progress to
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!